Transformative cholesterol-lowering drug acquired as part of $9.7 billion merger
Novartis (Basel, Switzerland) is set to acquire The Medicine Company (NJ, USA) for a price of $9.7 billion. Under the terms of the agreement, Novartis will also add inclisiran, a novel cholesterol-lowering drug, into their portfolio.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>